- Home
- AUTL vs KMDA Comparison
AUTL vs KMDA Comparison
Compare AUTL & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUTL
- KMDA
- Stock Information
- Founded
- AUTL 2014
- KMDA 1990
- Country
- AUTL United Kingdom
- KMDA Israel
- Employees
- AUTL N/A
- KMDA N/A
- Industry
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- AUTL Health Care
- KMDA Health Care
- Exchange
- AUTL Nasdaq
- KMDA Nasdaq
- Market Cap
- AUTL 368.6M
- KMDA 398.5M
- IPO Year
- AUTL 2018
- KMDA N/A
- Fundamental
- Price
- AUTL $1.37
- KMDA $7.05
- Analyst Decision
- AUTL Strong Buy
- KMDA Strong Buy
- Analyst Count
- AUTL 5
- KMDA 2
- Target Price
- AUTL $9.12
- KMDA $13.00
- AVG Volume (30 Days)
- AUTL 2.4M
- KMDA 65.3K
- Earning Date
- AUTL 11-12-2025
- KMDA 11-10-2025
- Dividend Yield
- AUTL N/A
- KMDA 2.86%
- EPS Growth
- AUTL N/A
- KMDA 30.41
- EPS
- AUTL N/A
- KMDA 0.35
- Revenue
- AUTL $51,128,000.00
- KMDA $174,787,000.00
- Revenue This Year
- AUTL $643.50
- KMDA $14.49
- Revenue Next Year
- AUTL $108.69
- KMDA $10.12
- P/E Ratio
- AUTL N/A
- KMDA $20.35
- Revenue Growth
- AUTL 406.67
- KMDA 10.36
- 52 Week Low
- AUTL $1.11
- KMDA $5.54
- 52 Week High
- AUTL $3.45
- KMDA $9.16
- Technical
- Relative Strength Index (RSI)
- AUTL 44.06
- KMDA 52.07
- Support Level
- AUTL $1.23
- KMDA $6.55
- Resistance Level
- AUTL $1.52
- KMDA $7.34
- Average True Range (ATR)
- AUTL 0.11
- KMDA 0.19
- MACD
- AUTL -0.01
- KMDA 0.03
- Stochastic Oscillator
- AUTL 31.76
- KMDA 55.70
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.